BTIG Reiterates Buy on Outlook Therapeutics, Maintains $50 Price Target

Benzinga · 10/18 15:25
BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $50 price target.